University of Michigan–Ann Arbor-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

2020

  1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 271-282